Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Aubagio (teriflunomide)
- caffeine
Interactions between your drugs
caffeine teriflunomide
Applies to: caffeine, Aubagio (teriflunomide)
MONITOR: Coadministration with teriflunomide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is increased clearance due to teriflunomide-mediated induction of CYP450 1A2. Multiple doses of teriflunomide decreased mean Cmax and AUC of caffeine, a known CYP450 1A2 substrate, by 18% and 55%, respectively.
MANAGEMENT: Caution is advised if teriflunomide is used concomitantly with drugs that are substrates of CYP450 1A2. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever teriflunomide is added to or withdrawn from therapy with these drugs.
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2012) "Product Information. Aubagio (teriflunomide)." Genzyme Corporation
Drug and food/lifestyle interactions
caffeine food/lifestyle
Applies to: caffeine
The effect of grapefruit juice on the pharmacologic activity of caffeine is controversial. One report suggests that grapefruit juice increases the effect of caffeine. The proposed mechanism is inhibition of cytochrome P-450 metabolism of caffeine. However, a well-conducted pharmacokinetic/pharmacodynamic study did not demonstrate this effect. The clinical significance of this potential interaction is unknown.
References (2)
- (1995) "Grapefruit juice interactions with drugs." Med Lett Drugs Ther, 37, p. 73-4
- Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR (1996) "Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics." Pharmacotherapy, 16, p. 1046-52
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Copaxone
Copaxone is used to treat relapsing forms of multiple sclerosis (MS) in adults (including ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tecfidera
Tecfidera (dimethyl fumarate) is used to treat relapsing forms of multiple sclerosis. Learn about ...
Avonex
Avonex is an interferon used to treat relapsing multiple sclerosis. It is given by injection into a ...
Gilenya
Gilenya (fingolimod) is used to treat relapsing forms of multiple sclerosis. Includes Gilenya side ...
Tysabri
Tysabri is used to treat multiple sclerosis and Crohn's disease. Learn about side effects ...
Betaseron
Betaseron is used to treat relapsing multiple sclerosis (MS). Learn about side effects ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.